156 related articles for article (PubMed ID: 30896626)
1. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case report.
Nakao S; Masuda T; Sakamoto S; Yamaguchi K; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Medicine (Baltimore); 2019 Mar; 98(12):e14821. PubMed ID: 30896626
[TBL] [Abstract][Full Text] [Related]
2. Edoxaban: A direct oral anticoagulant.
Poulakos M; Walker JN; Baig U; David T
Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism.
Hotta T; Tsubata Y; Hamai K; Tanino A; Kobayashi M; Nakamura A; Sugisaka J; Hongoh M; Ishihara N; Ishikawa N; Yamasaki M; Fujitaka K; Kubota T; Nishimura N; Isobe T
Respir Investig; 2021 May; 59(3):327-334. PubMed ID: 33386292
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
AlHajri L; Jabbari S; AlEmad H; AlMahri K; AlMahri M; AlKitbi N
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):230-238. PubMed ID: 27811198
[TBL] [Abstract][Full Text] [Related]
5. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
6. Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Shirley M; Dhillon S
Drugs; 2015 Nov; 75(17):2025-34. PubMed ID: 26546477
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson CM; Finks SW
Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
[TBL] [Abstract][Full Text] [Related]
8. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Sprynger M
Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
[TBL] [Abstract][Full Text] [Related]
9. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
[TBL] [Abstract][Full Text] [Related]
10. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
van Es N; Di Nisio M; Bleker SM; Segers A; Mercuri MF; Schwocho L; Kakkar A; Weitz JI; Beyer-Westendorf J; Boda Z; Carrier M; Chlumsky J; Décousus H; Garcia D; Gibbs H; Kamphuisen PW; Monreal M; Ockelford P; Pabinger I; Verhamme P; Grosso MA; Büller HR; Raskob GE
Thromb Haemost; 2015 Nov; 114(6):1268-76. PubMed ID: 26271200
[TBL] [Abstract][Full Text] [Related]
12. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
[TBL] [Abstract][Full Text] [Related]
13. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
Medina A; Raskob G; Ageno W; Cohen AT; Brekelmans MPA; Chen CZ; Grosso MA; Mercuri MF; Segers A; Verhamme P; Vanassche T; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Thromb Haemost; 2017 Dec; 117(12):2406-2414. PubMed ID: 29212128
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
[TBL] [Abstract][Full Text] [Related]
15. Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy.
Puccetti L; Sammartano V; Calzoni P; Bacchiarri F; Santoni A; Fineschi D; Bocchia M
Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):54-58. PubMed ID: 35049019
[TBL] [Abstract][Full Text] [Related]
16. Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
Shoji T; Mizugaki H; Ikezawa Y; Furuta M; Takashima Y; Kikuchi H; Goudarzi H; Asahina H; Kikuchi J; Kikuchi E; Sakakibara-Konishi J; Shinagawa N; Tsujino I; Nishimura M
Intern Med; 2018 Jun; 57(12):1769-1772. PubMed ID: 29434159
[TBL] [Abstract][Full Text] [Related]
17. Clinical Trial Based Rationale for the Successful Use of DOAC in the Treatment of Cerebral Venous Sinus Thrombosis (CVST): A Case Report.
Bando T; Ueno Y; Shimo D; Kuroyama T; Mikami K; Hori S; Hirai O
J Stroke Cerebrovasc Dis; 2020 Nov; 29(11):105261. PubMed ID: 33066921
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
Ikeda S; Koga S; Yamagata Y; Eguchi M; Sato D; Muroya T; Yonekura T; Tsuneto A; Yoshimuta T; Koide Y; Kawano H; Maemura K
J Cardiol; 2018 Aug; 72(2):120-127. PubMed ID: 29661489
[TBL] [Abstract][Full Text] [Related]
19. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
